

Hypercolour Deep-field The Biochemical Imaging Platform for Eye Care

Market: Serviceable AU + US market supports ~7,500 cameras and about \$1.6B in annual software revenue at \$30 per scan; global opportunity >\$5B:

- High-volume use cases across age-related macular degeneration, diabetic eye disease, glaucoma and ocular tumours
- Long-term upside from systemic insights as evidence matures

Current solution: Clinics rely on structural imaging (fundus photos, OCT). These tools confirm damage after it has happened. AI tools on mixed third-party devices struggle because capture is not calibrated or governed, which limits trust and regulatory acceptance.

Problem: Clinicians lack an early, actionable signal and short-term risk estimates to guide recall and treatment. Uncontrolled data pipelines make validation expensive and slow, especially for longitudinal and prognostic claims.

Our solution

- **Camera + Cloud AI.** A clinic-ready hyperspectral camera takes a 0.3-second retinal scan; calibrated data go to our cloud powered by an AI model.
- **Outputs.** Familiar clinical outputs today; monitoring and short-term risk added later by software update, no new hardware.
- **Business model.** Modest-margin device (~\$30k) plus \$30 per-scan software; value compounds as new modules are enabled without new hardware.



Dr Xavier Hadoux
Co-founder & CEO



Prof Peter van Wijngaarden
Co-founder & CMO



From research to clinic:




- ✓ 3 years of extensive prototyping
- ✓ Extensive user feedback and clinical testing
- ✓ 4 years of continuous use of 5 MVPs
- ✓ ISO 13485 commercial device 70% complete


Proof of principle studies




Tumour margin ($n=71$)
95% agreement vs specialist



Geographic atrophy ($n=81$)
85% agreement vs autofluorescence



Glaucoma nerve fibre layer ($n=80$)
0.88 correlation vs OCT thickness



Diabetic retinopathy ischemia ($n=45$)
88% agreement vs angiography

Next steps

- Finalise engineering; submit TGA/FDA (device + cloud).
- Launch pilot manufacturing; ship initial units.
- Prepare biomarker study plans.

Partnership or funding opportunities to accelerate commercialisation. Contact stan@cera.org.au